CORRESP Filing
HCW Biologics Inc.
Date: Feb. 11, 2026 · CIK: 0001828673 · Accession: 0001193125-26-047207
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-293396
Letter
Re: HCW Biologics Inc. Registration Statement on Form S-1; Commission File No. 333-293396 Dear Mr. McNamara: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, HCW Biologics Inc. (the “Company”) hereby requests that the effectiveness of the Company’s Registration Statement on Form S-1 (File No. 333-293396), filed on February 11, 2026, be accelerated by the U.S. Securities and Exchange Commission to 5:00 p.m. Eastern Time on Friday, February 13, 2026, or as soon thereafter as is practicable. The Company hereby authorizes James Groth or Jeny Zarmon of Clark Hill PLC to orally modify or withdraw this request for acceleration. Please contact Mr. Groth at (312) 701-6830 or Ms. Zarmon at (609) 785-2918 with any questions you may have concerning this request, and please notify them when this request for acceleration has been granted. Thank you for your courtesy and cooperation in this matter. Very truly yours,
February 11, 2026 VIA EDGAR AND E-MAIL Mr. James McNamara Office of Life Sciences Division of Corporate Finance U.S. Securities and Exchange Commission 100 F. Street, N.E. Washington, DC 20549-7010
HCW BIOLOGICS INC.
By:
/s/ Hing Wong
Hing Wong, Founder and CEO HCW Biologics acceleration request for S-1 February 2026
2929 N Commerce Parkway | Miramar, Florida 33025, USA | Phone 954-842-2024 | Fax 954-842-2037 |
Show Raw Text
CORRESP 1 filename1.htm CORRESP February 11, 2026 VIA EDGAR AND E-MAIL Mr. James McNamara Office of Life Sciences Division of Corporate Finance U.S. Securities and Exchange Commission 100 F. Street, N.E. Washington, DC 20549-7010 Re: HCW Biologics Inc. Registration Statement on Form S-1; Commission File No. 333-293396 Dear Mr. McNamara: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, HCW Biologics Inc. (the “Company”) hereby requests that the effectiveness of the Company’s Registration Statement on Form S-1 (File No. 333-293396), filed on February 11, 2026, be accelerated by the U.S. Securities and Exchange Commission to 5:00 p.m. Eastern Time on Friday, February 13, 2026, or as soon thereafter as is practicable. The Company hereby authorizes James Groth or Jeny Zarmon of Clark Hill PLC to orally modify or withdraw this request for acceleration. Please contact Mr. Groth at (312) 701-6830 or Ms. Zarmon at (609) 785-2918 with any questions you may have concerning this request, and please notify them when this request for acceleration has been granted. Thank you for your courtesy and cooperation in this matter. Very truly yours, HCW BIOLOGICS INC. By: /s/ Hing Wong Hing Wong, Founder and CEO HCW Biologics acceleration request for S-1 February 2026 2929 N Commerce Parkway | Miramar, Florida 33025, USA | Phone 954-842-2024 | Fax 954-842-2037 |